antibody

Anti-Human CTLA-4, FITC, (clone: A3.4H2.H12), (mouse IgG2ak)

MBS520258

0.1 mg

285 USD

monoclonal

mouse

FITC

A3.4H2.H12

flow cytometry, FACS

Antibody

Anti-Human CTLA-4, FITC, (clone: A3.4H2.H12), (mouse IgG2ak)

CTLA-4

CTLA-4, FITC, (clone: A3.4H2.H12), (mouse IgG2ak); FITC Anti-Human CTLA-4 (CD152) Monoclonal Antibody

cytotoxic T-lymphocyte protein 4 isoform CTLA4-TM; Cytotoxic T-lymphocyte protein 4; cytotoxic T-lymphocyte protein 4; CD152 isoform; celiac disease 3; cytotoxic T-lymphocyte antigen 4; cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4; cytotoxic T-lymphocyte-associated protein 4; Cytotoxic T-lymphocyte-associated antigen 4

CTLA-4

CTLA4; CTLA4; CD; GSE; GRD4; CD152; CTLA-4; IDDM12; CELIAC3; CD152; CTLA-4

CTLA4_HUMAN

Monoclonal

Mouse IgG2akappa

A3.4H2.H12

Mouse

Human

223

CTLA4 (Human CTLA-4 (CD152))

FITC (FITC conjugated Ig buffered in PBS, 0.02% NaN3 and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml. (Purified from ascitic fluid via Protein G Chromatography))

Antibody Concentration: 0.1 mg/ml

Store at 4 degree C. For long term storage, aliquot and freeze unused portion at -20 degree C in volumes appropriate for single usage. Avoid multiple freeze/thaw cycles and prolonged exposure to light.

Flow Cytometry (FC/FACS)

Immunogen: Activated T cells. Donor: Balb/c mouse. Fusion Partner: SP 2/0 myeloma

Presentation: 100 ìug FITC conjugated Ig buffered in PBS, 0.02% NaN3 and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml.

Human CTLA-4 (also known as Cytotoxic T lymphocyte-associated antigen-4, CD152) is a structural homologue of T cell co-stimulatory receptor CD28. CTLA-4 binds to the same ligands (CD80 and CD86) as CD28 but with much higher avidity. It is expressed at very low levels on the cell surface of activated T cells, and is found primarily in the post-Golgi or endosomal compartments of the cell.There is a high degree of overall homology between human and mouse CTLA-4 (>70%), and the cytoplasmic domains of the human, mouse and rabbit sequences are completely conserved. CD152 antibodies have shown both stimulatory and negative regulatory roles in functional experiments. This antibody is suitable for use in Intracellular Flow Cytometry.

21361212

NP_005205.2

NM_005214.4

P16410

24,656 Da

Adaptive Immune System Pathway (366160); Autoimmune Thyroid Disease Pathway (83121); Autoimmune Thyroid Disease Pathway (533); CTLA4 Inhibitory Signaling Pathway (119556); Calcineurin-regulated NFAT-dependent Transcription In Lymphocytes Pathway (137993); Cell Adhesion Molecules (CAMs) Pathway (83069); Cell Adhesion Molecules (CAMs) Pathway (480); Costimulation By The CD28 Family Pathway (119552); Immune System Pathway (106386); Rheumatoid Arthritis Pathway (200309)

This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases. [provided by RefSeq, Jul 2008]

Function: Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. Ref.11 Ref.17. Subunit structure: Homodimer; disulfide-linked. Binds to CD80/B7-1 and CD86/B7.2. Ref.21 Ref.22 Ref.23. Subcellular location: Cell membrane; Single-pass type I membrane protein. Note: Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation;. Ref.18. Tissue specificity: Widely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation. Ref.1 Ref.10 Ref.17. Post-translational modification: N-glycosylation is important for dimerization.Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface. Polymorphism: Genetic variations in CTLA4 are associated with susceptibility to several autoimmune disorders. They influence responsiveness to hepatitis B virus (HBV) infection [. MIM:610424]. Involvement in disease: Systemic lupus erythematosus (SLE) [MIM:152700]: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Ref.27Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism. Ref.27Diabetes mellitus, insulin-dependent, 12 (IDDM12) [MIM:601388]: A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Ref.24 Ref.27Celiac disease 3 (CELIAC3) [MIM:609755]: A multifactorial, chronic disorder of the small intestine caused by intolerance to gluten. It is characterized by immune-mediated enteropathy associated with failed intestinal absorption, and malnutrition. In predisposed individuals, the ingestion of gluten-containing food such as wheat and rye induces a flat jejunal mucosa with infiltration of lymphocytes.Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Ref.25 Ref.27 Ref.31. Pharmaceutical use: Engineered fusion proteins consisting of the extracellular domain of CTLA4 and the IgG Fc region (Ctla4-Ig), inhibit T-cell-dependent antibody responses, and are used as immunosuppressive agents. They are soluble, have an enhanced affinity for B7 ligands and act as a competitive inhibitor of CD28. Sequence similarities: Contains 1 Ig-like V-type (immunoglobulin-like) domain.

0.1 mg

285 USD